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Abstract
The mitochondrial Bit1 (Bcl-2 inhibitor of transcription 1) protein is a part of an apoptotic pathway that is uniquely regulated
by integrin-mediated attachment. As an anoikis effector, Bit1 is released into the cytoplasm following loss of cell attachment
and induces a caspase-independent form of apoptosis. Considering that anoikis resistance is a critical determinant of
transformation, we hypothesized that cancer cells may circumvent the Bit1 apoptotic pathway to attain anchorage-
independence and tumorigenic potential. Here, we provide the first evidence of the tumor suppressive effect of Bit1
through a mechanism involving anoikis induction in human lung adenocarcinoma derived A549 cells. Restitution of Bit1 in
anoikis resistant A549 cells is sufficient to induce detachment induced-apoptosis despite defect in caspase activation and
impairs their anchorage-independent growth. Conversely, stable downregulation of Bit1 in these cells significantly enhances
their anoikis resistance and anchorage-independent growth. The Bit1 knockdown cells exhibit significantly enhanced
tumorigenecity in vivo. It has been previously shown that the nuclear TLE1 corepressor is a putative oncogene in lung
cancer, and we show here that TLE1 blocks Bit1 mediated anoikis in part by sequestering the pro-apoptotic partner of Bit1,
the Amino-terminal Enhancer of Split (AES) protein, in the nucleus. Taken together, these findings suggest a tumor
suppressive role of the caspase-independent anoikis effector Bit1 in lung cancer. Consistent with its role as a tumor
suppressor, we have found that Bit1 is downregulated in human non-small cell lung cancer (NSCLC) tissues.
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Introduction
A critical determinant of a malignant epithelial phenotype is
anchorage independence. The loss of anchorage dependence to
the extracellular matrix by malignant cells enables them to grow in
the absence of cell adhesion, to propagate in a three dimensional
matrix, to invade adjacent tissues, and metastasize to distant
organs [1,2]. The molecular mechanisms and cellular pathways
underlying anchorage-independence of cancer cells have been
extensively studied [3,4], and most of these molecular alterations
confer malignant cells the ability to evade the anoikis program
which is in place in normal cells. Considering that breakdown of
anoikis control contributes to growth and malignancy of many
solid tumors, restoring anoikis sensitivity represents an important
therapeutic strategy in curtailing tumor aggressiveness and
metastasis. Hence, identification of novel molecular targets of
the anoikis-mediated cell death pathway has significant therapeu-
tic implications.
Two apoptotic pathways, the mitochondrial (intrinsic) and cell
death receptor (extrinsic), have been shown to regulate the anoikis
process. Following detachment-induced loss of integrin-mediated
survival signalling, the intrinsic apoptotic pathway is triggered
through activation of the pro-apoptotic members of the BCL
family of proteins (including Bax, Bad, Bid and Bim). These
proteins trigger permeabilization of the outer mitochondrial
membrane leading to cytosolic release of cytochrome c and
downstream activation of caspase enzymes [5,6]. This mitochon-
drial-dependent caspase activation loop, which can be further
amplified via downregulation of expression of the anti-apoptotic
Bcl family members (such as Bcl-2 and Bcl-xL) which function in
guarding mitochondrial integrity [7], may ultimately lead to DNA
fragmentation and cell death. The death receptor (extrinsic)
pathway depends upon the binding of death ligands (Fas or
TRAIL) to death receptor and utilizes the formation of a death-
inducing signaling complex (DISC) in activating the downstream
caspase-8. This death receptor-mediated caspase 8 activation may
effect destabilization of the mitochondrial membrane leading to
apoptosis [8,9]. Although convergence and crosstalk between
extrinsic and intrinsic apoptotic pathways exist at various levels,
both pathways rely on caspase activation loop to effect cell death.
However, evidences have emerged indicating the existence of
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caspase-independent mechanisms in anoikis [10,11]. In particular,
inhibition of caspase activation either through overexpression of
Bcl-2 or treatment with global caspase inhibitors is unable to block
basal anoikis in tumor cells as assessed by DNA ladder analysis
[10]. The alternative caspase-independent mode of anoikis is an
important therapeutic target in tumors that exhibit a disabled
caspase-dependent apoptosis pathway.
Ruoslahti and colleagues have recently identified a novel
integrin-dependent apoptotic pathway that is mediated by the
mitochondrial Bit1 (Bcl2, inhibitor of transcription 1) protein [11].
Following loss of integrin-mediated cell attachment, Bit1 is
released into the cytoplasm, forms a complex with the transcrip-
tional coregulator AES, and subsequently induces a caspase-
independent mode of apoptosis. While several known anti-
apoptotic factors such as Bcl-2, Bcl-xl, Akt are ineffective in
blocking Bit1 apoptosis, integrin-mediated attachment is the sole
anti-apoptotic treatment that can suppress Bit1 apoptosis function
[11]. Considering that integrin-mediated cell adhesion, particu-
larly the a5b1 integrin, is the only up-stream treatment that can
block the Bit1 apoptosis pathway, Bit1 may play an important role
in anoikis as a guardian of anchorage dependence [11–15]. Based
on the inability of caspase inhibitors to inhibit Bit1 apoptosis and
the absence of caspase activation in Bit1 transfected cells, the Bit1
pathway may represent one of the caspase-independent anoikis
mechanisms in malignant cells [11]. Hence, the Bit1 apoptotic
pathway appears to be an attractive therapeutic target in
circumventing anoikis resistance particularly in tumor cells that
exhibit deficient caspase activity. Utilization of Bit1 as a
therapeutic target requires a detailed examination of the
mechanism of its apoptosis function, which we have found to be
dependent in part on turning off a survival-promoting gene
transcription program controlled by the groucho transcriptional
corepressor TLE1 [15].
The role of Bit1 in anoikis has been demonstrated in several
transformed cell lines. Through genetic manipulation approaches,
we have shown that exogenous expression of mitochondrial Bit1
blocks the anoikis resistance of several tumor cell lines while
downregulation of endogenous Bit1 expression further confounds
their anoikis insensitivity [11–15]. Since the acquisition of anoikis
resistance is an important determinant of neoplastic transforma-
tion and metastatic potential [1,2], suppression of the Bit1 anoikis
pathway in malignant cells may contribute to cancer progression,
particularly in the acquisition of advanced tumorigenic and
metastatic behaviour. Indeed, our previous studies demonstrated
that Bit1 may function as a suppressor of metastasis in vivo [14].
Although the exact mechanism underlying its metastasis inhibitory
effect remains to be defined, the Bit1 anoikis inducing function
may play a rate limiting step in the metastasis process.
Interestingly, the role of Bit1 in tumorigenesis has not been
demonstrated to date.
To further address the role of Bit1 in cancer formation, we have
performed preliminary online database search to examine whether
Bit1 expression is altered in various types of human tumors as
compared to their normal counterparts. Intriguingly, we have
found that Bit1 expression is selectively and significantly
suppressed in lung cancer. This preliminary finding, in conjunc-
tion with the recent evidence documenting that TLE1 may
function as a lung specific oncogene [16], has prompted us to
investigate the significance of the Bit1 apoptotic pathway in the
anoikis insensitivity and tumorigenic potential of Non Small Cell
Lung Carcinoma (NSCLC), which is the most aggressive form of
lung cancer and is highly chemoresistant in part due to a deficient
caspase-dependent apoptosis pathway [17,18]. Here, we show that
exogenous Bit1 circumvents the anoikis resistance of human lung
adenocarcinoma A549 cells through activation of caspase-
independent apoptosis and impairs their anchorage-independent
growth. Consistently, knockdown of endogenous Bit1 in these cells
further enhances their anoikis insensitivity and anchorage-inde-
pendent potential in vitro and potentiates their tumorigenic growth
in vivo. In line with its tumor suppressive function, Bit1 expression
was found to be downregulated in NSCLC tumors.
Materials and Methods
Cell culture and transfection assays
NSCLC A549 and H460 cell lines obtained from American
Type Culture Collection (ATCC) were cultured in Dulbecco’s
modified Eagle’s medium (DMEM) with glutamine containing
10% fetal bovine serum, penicillin, and streptomycin. The stable
A549 derived control and Bit1 shRNA pool of cells were
maintained in Dulbecco’s modified Eagle’s medium (DMEM)
with glutamine containing 10% fetal bovine serum, penicillin,
streptomycin, and 1 mg/ml puromycin (Invitrogen). Transient
transfection assays were carried out with lipofectamine 2000
(Invitrogen) for A549 cells and Lipofectamine LTX reagent
(Invitrogen) for H460 cells in OPTI-MEM (Invitrogen) according
to the manufacturer’s protocol with the total amount of plasmid
used per transfection normalized with the corresponding empty
vector construct.
Chemical reagents, antibodies, and plasmids
The Poly(2-hydroxyethyl methacrylate (Polyhema) and the
mouse monoclonal anti-FLAG, anti-AES, anti-GFP and anti-B-
actin antibodies were purchased from Sigma (St. Louis, MO). The
polyclonal anti-TLE1 antibody was obtained from Abcam (Cam-
bridge, MA). The caspase inhibitor zVad-fmk and the anti-myc
antibody were purchased from Calbiochem (La Jolla, CA). The
anti-caspase-3, anti-cleaved caspase-3, Bcl-2, Bcl-xl, Bax, Bad, and
anti-PARP antibodies were obtained from Cell Signaling Tech-
nology (Beverly, MA). The mammalian expression vector encod-
ing for mitochondrial Bit1 were generated as described previously
[11]. The GFP-TLE1 plasmids were obtained from Origene
(Rockville, MD). The construct encoding the cell death domain
(CDD) of Bit1 was obtained from Dr. Erkki Ruoslahti (Sanford-
Burnham Medical Research Institute) and was previously charac-
terized [19].
SiRNA and shRNA transfection
The TLE1 specific siRNAs and the control non-targeting
siRNAs were purchased from Invitrogen (Carlsbad, CA). For
transient transfection experiments, A549 cells (26105) were
transfected with 25 mM of each siRNA using the Lipofectamine
RNAiMAX transfection reagent (Invitrogen). 48 hrs post-trans-
fection, cells were harvested and subjected to immunoblotting or
anoikis assays as described below. To generate stable A549 Bit1
knockdown and control pools, A549 parental cells were transfected
with pRS vector containing the short hairpin RNA against TLE1
(Origene) or the non-targeting scrambled shRNA (Origene). 48 h
post-transfection, 1 mg/ml puromycin (Invitrogen) was added to
the medium to select for puromycin-resistant clones. Individual
puromycin-resistant clones were screened for Bit1 downregulation
by immunoblotting using a specific antibody to Bit11 [15]. Two
Bit1 shRNA knockdown-positive clones and two control shRNA
clones were pooled for further characterization.
Analysis of apoptosis, anoikis, and cell viability
Apoptosis was determined by quantitating the level of cytosolic
nucleosomal fragments with the use of Cell Death Detection
Bit1 Exhibits Tumor Suppressive Function in Lung Cancer
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ELISA kit (Roche Molecular Biochemicals) per the manufacturer’s
instructions [14,15]. To assess for anoikis cell death, cells were
plated onto Polyhema coated 96 well plates in complete growth
medium containing 0.5% methylcellulose at a density of 1.06104/
well at various time points as previously described [14,15].
Detached cells were then collected and subjected to the Cell Death
ELISA apoptosis assay. Cell viability was quantified by alarmar
blue staining (Invitrogen) and subsequent fluorescence reading
(485 nm excitation wavelength and 520 nm emission wavelength)
using the microplate reader (BioTek Instruments).
Cell proliferation and soft agar assays
Anchorage-dependent growth was determined by plating cells
in a volume of 150 ml at a density of 2,000 cells per well in 96-well
plates. At each indicated time, the number of metabolically active
cells was measured with the use of MTT assay as described
previously [15]. Briefly, ten microliters of the MTT reagent at
5 mg/ml (Sigma) was added to each well in a 96-well plate. The
plate was then incubated at 37uC, 5% CO2 for 3 h. Afterwards,
the resulting MTT precipitate was dissolved in 100 ul of a 50%
MeOH-50% DMSO solution and subjected to a 550 nm
absorbance reading via a microplate reader (BioTek Instruments).
The anchorage-independent growth of cells was assesed using the
96-well plate format [15]. As described previously, 5,000 cells in
0.3% agar solution was plated onto wells precoated with 0.6%
agar in culture medium. The growth of the resulting colonies was
quantified by alarmar blue staining (Invitrogen) and fluorescence
reading at 485 nm excitation wavelength and 520 nm emission
wavelength with a microplate plate reader.
Caspase activation assay
Caspase-3 activity was determined fluorometrically using the
substrate Ac-DEVD-AFC substrate and was performed according
to manufacturer’s instructions (Roche Applied Science).
Protein preparation and western blotting assays
Protein preparation and western blotting were performed as
described previously [14,15]. Briefly, cells were harvested 24–
48 hr after transfection with various constructs or siRNAs by
adding ice-cold NP-40 lysis buffer (1% NP-40; 20 mM Tris-HCL
[pH 7.4]; 150 mM NaCl; 10% glycerol, 2 mM sodium vanadate;
1 mM henylmethylsulfonyl fluoride; 10 mg/ml leupeptine; and
5 mg/ml aprotinin) and incubated at 4uC for 20 min. For
immunoblot analysis, equal amounts of proteins were resolved
on 4–20% gradient Tris-glycine gels (Invitrogen) and electropho-
retically transferred to nitrocellulose membrane. The membranes
were incubated with primary antibodies overnight at 4uC followed
by secondary antibodies conjugated with horseradish peroxidase.
Membranes were developed using the ECL detection system.
Subcellular fractionation
Subcellular fractionation was performed as described previously
[15]. Briefly, transfected cells cultured in attached or detached
conditions at the indicated times were harvested washed once with
PBS, resuspended in 1 ml of isotonic mitochondrial buffer
(250 mM mannitol, 70 mM sucrose, 1 mM EDTA, 10 mM
HEPES [pH 7.5]), and homogenized with 40 strokes in a Dounce
homogenizer. The lysates were centrifuged at 5006g for 5 min to
eliminate nuclei and unbroken cells. The supernatant was further
centrifuged at 10,0006 g for 30 min at 4uC to isolate the
mitochondrial enriched pellet. The resulting cytosolic supernatant
was subjected to SDS-PAGE electrophoresis and immunoblotting.
For separation of cytosol and the nuclear fraction, the NE-PER
nuclear isolation kit (Pierce, No. 78833) was used and performed
as prescribed by the manufacturer [15]. The protein concentration
in the different fractions was quantified using the Bio-Rad protein
assay kit with BSA as the standard.
Coimmunoprecitation assay
Coimmunoprecipitation assay was performed as described
previously [15]. Briefly, transfected cells were harvested by
washing once with PBS and resuspended in ice-cold Nonidet P-
40 lysis buffer (1% Nonidet P-40, 20 mm Tris-HCl, pH 7.4,
150 mm NaCl, 10% glycerol, 2 mm sodium vanadate, 1 mm
phenylmethylsulfonyl fluoride, 10 mg/ml leupeptin, and 5 mg/ml
aprotinin) followed by a 20-min incubation at 4uC. Cell debris was
removed by centrifugation. Myc-tagged Bit1 was immunoprecip-
itated with anti-Myc-agarose conjugate (Abcam) while GFP-
tagged TLE1 was immunoprecipitated with anti-GFP-agarose
(Medical and Biological Laboratories). The immunoprecipitate
was thoroughly washed with lysis buffer. Bound proteins were
resolved by SDS-PAGE, and Western blotting was performed
using the corresponding antibody.
In vivo tumorigenesis assay
All procedures were done according to protocols approved by
the Institutional Committee for Use and Care of Laboratory
Animals of Xavier University of Louisiana Institutional Animal
Care and Use Committee (IACUC, Approval Number 060911-
001BI). Eight-week-old female athymic nude mice (BALB/c) were
used for the tumorigenesis assays. The A549 derived control
shRNA and Bit1 shRNA cells (1.06106) were injected subcuta-
neously. The tumor sizes were measured periodically with a
calliper, and tumor volume was determined with the formula
(d16d22)/2 where d1 represents the larger diameter and d2 the
smaller diameter. Mice were sacrificed when the primary tumors
reached 2 cm in diameter.
In Situ Apoptosis Detection
Detection of apoptotic cells in control shRNA and Bit1 shRNA
tumor sections was performed using the DeadEnd Colorimetric
TUNEL System (Promega) following the manufacturer’s instruc-
tions. Briefly, sections were deparaffinized, rehydrated, and
incubated with Proteinase K for 20 min at room temperature.
After washing with PBS, the sections were incubated with a
working concentration of recombinant Terminal Deoxynucleoti-
dyl Transferase (rTdT) at 37uC for 1 h. The sections were the
washed with PBS and immersed in 0.3% hydrogen peroxide to
block endogenous peroxidase activity. The sections were subse-
quently washed with PBS and incubated with the streptavidin-
HRP solution. The resulting dark brown signal was visualized with
Diaminobenzidine (DAB) as chromogen.
Human lung tumor tissue array analysis
Human tumor tissue array slides containing squamous cell
carcinomas, adenocarcinoma, larger cell carcinoma, and matched
normal lung tissues were obtained from US Biomax, Inc.
(Rockville, MD). The immunohistochemistry procedure was
performed by Biomax Inc. on two tissue microarray slides. As
described previously [14,15], tissue array slides were deparaffi-
nised, hydrated and subjected to antigen retrieval. The slides were
then incubated in 2.5% normal horse serum for 30 min at room
temperature followed by incubation with the primary antibody
(1:100 dilution) for 1 h at room temperature. The affinity purified
rabbit anti-Bit1 antibody (HPA012897) which was previously
tested for its specificity [14,15] was purchased from Sigma. Rabbit
Bit1 Exhibits Tumor Suppressive Function in Lung Cancer
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normal serum was used as negative control antibody to replace the
primary antibody on control slide with 1 hr incubation. Tissue
array slides were then washed and incubated with ImmPRESS
reagent (Vector Laboratories) followed by treatment with perox-
idise substrate DAB solution (DAKO Cytomation). The slides
were scored for average Bit1 staining intensity by two investigators
with no knowledge of the pathologic status of the samples. The
average staining was graded as 0, no staining; 1, slight staining; 2,
moderate staining; and 3, strong staining.
Statistical analysis
Data are presented as means (6S.E.). For western blots and
anoikis assays, experiments were performed at least three times
with triplicates. Statistical differences between groups were
established at a P value,0.05 using the two-tailed Student’s t
test. For lung tumor tissue array analysis, a one-way ANOVA with
subsequent post hoc testing using the Tukey-Kramer multiple
comparison test was used to compare the average staining intensity
of each case type [14,15]. All calculations were done using the
NCSS statistical software (NCSS, Kasville, UT)
Results
The Anoikis Resistance of A549 cells is Associated with
Lack of Significant Caspase Activity
NSCLC cells are notoriously known to be resistant to various
forms of apoptotic stimuli including death receptor stimulation,
cytotoxic drugs, and radiation. The ability of NSCLC to evade
apoptosis has been attributed in part to an inefficient caspase-
independent machinery [17,18]. However, the mechanisms of
how NSCLC blocks anoikis have not been thoroughly examined.
To address the potential utility of caspase-independent mecha-
nisms in circumventing the anoikis resistance of NSCLC cells, we
first examined the contribution of the caspase pathway in anoikis.
Consistent with previous reports [20], the NSCLC cell line A549
showed very low level of apoptosis when cultured in suspension
(Figure 1A). Staurosporin (STS), a potent kinase inhibitor,
significantly induced apoptosis in these cells (Figure 1A). To
address the role of caspase dependent pathway in the anoikis
blockade in A549 cells, we examined the cytosolic release of
mitochondrial cytochrome c protein (a pivotal factor in activating
the downstream caspase effectors) during detachment. In contrast
to STS treated cells which showed substantial amounts of
cytochrome c in the cytoplasm, detached cells exhibited only
trace amounts of cytochrome c in the cytoplasmic fraction
(Figure 1B). Next, we monitored the activation of the downstream
or executioner caspase 3 via the cleavage of the fluorescent
caspase-3 substrate (Figure 1C) and the processing of pro-caspase 3
through immunoblotting (Figure 1D). In line with the lack of
significant cytosolic release of cytochrome c, detached A549 cells
showed no substantial caspase 3 activation (Figure 1C) and
displayed no processing of pro-caspase 3 (Figure 1D). The end
target of the caspase machinery is to cleave the nuclear poly (ADP-
ribose) polymerase (PARP) protein [5,6]. As shown in Fig. 1E,
PARP remained relatively intact in its native 116 kDa form in
detached A549 cells (Figure 1E). Taken together, these findings
indicate that the anoikis resistance of A549 cells is associated with
an inefficient cytochrome c/caspase-dependent cell death path-
way.
Bit1 Impairs the Anoikis Resistance of Lung Carcinoma
cells
Considering the lack of significant detachment-induced caspase
activation in A549 cells, we then explored the role of the Bit1 cell
death pathway in the anchorage-independent survival of these
cells. We increased the expression of mitochondrial Bit1 in A549
cells via transfection with a Bit1 construct that expresses the Bit1
protein exclusively in the mitochondria (Bit1 mito) [11,15], and
tested the cells’ ability to survive in the absence of attachment from
the ECM. The Bit1 mito and control transfected cells had the
same level of spontaneous apoptosis when grown attached to a
culture dish (Figure 2A). In striking contrast, the Bit1 mito
transfected cells exhibited significantly increased apoptosis than
the control cells upon detachment. Similar results were found
when Bit1 mito was introduced into human NSCLC H460 cell
line (Figure S1). To address the specificity of the anoikis induction
by Bit1 mito, we targeted Bit1 expression in the cytoplasm of A549
cells with the use of a Bit1 construct that contains a tag at the N-
terminal region of the Bit1 protein (Bit1 cyto) [11,15]. Exogenous
expression of cytoplasmic localized Bit1 (Bit1 cyto) in A549
(Figure 2B) and H460 (Figure S2) cells triggered apoptosis. The
cell death domain (CDD) of Bit1 was recently mapped at the N-
terminal 62 amino acids and was shown to be effective in inducing
apoptosis in breast cancer cells [19]. Introduction of the CDD
peptide also resulted in apoptosis in A549 (Figure 2C) and H460
(Figure S3) cells. Further characterization of the Bit1 anoikis
pathway in A549 cells confirmed that Bit1 triggered cell death
independent of caspases. First, we found no significant processing
of the executioner caspase 3 in Bit1 transfected cells (Figure 2D).
Second, the downstream nuclear substrate of caspases, PARP,
remained intact (Figure 2D). Third, the pan-caspase inhibitor z-
Vad-fmk was ineffective in blocking Bit1-induced anoikis
(Figure 2E). Consistent with the lack of Bit1 effect on caspase
activation, the expression of the apoptosis family of regulators that
control the caspase-dependent mitochondrial apoptotic pathway
was not altered by Bit1 (Figure 2D). In particular, the steady state
levels of the anti-apoptotic Bcl-2 and Bcl-xl proteins as well as the
pro-apoptotic Bax and Bad proteins remained unchanged by
ectopic Bit1 in both attached and detached conditions. These
findings indicate that Bit1 can circumvent the anoikis resistance of
lung cancer cells through induction of a caspase-independent
apoptotic pathway.
To further confirm the role of Bit1 as an anoikis effector in lung
cancer, we examined whether knockdown of endogenous Bit1
expression will impact the anoikis insensitivity of A549 cells. We
reasoned that A549 cells will undergo anoikis upon prolonged
culture in suspension and if ablation of the Bit1 apoptotic pathway
may provide anoikis protection. Indeed, following a protracted
72 hr culture in suspension, the detached A549 cells eventually
showed evidence of apoptosis (Figure 3A). The observed anoikis
induction was associated with no significant processing of caspase
3 and PARP (Figure 3B), indicating that alternative cell death
mechanism(s) other than the caspase-dependent pathway is
involved. We then downregulated Bit1 expression in A549 cells
via short-interfering RNAs (siRNAs) and subjected the Bit1 and
control siRNA treated cells to anoikis assay. Two Bit1 specific
siRNAs #1 and #2 showed a significant 70–80% downregulation
of Bit1 expression (Figure 3C). As compared to the A549 parental
or control siRNA treated cells, the Bit1 siRNA transfected cells
exhibited decreased apoptosis following a 72 h culture in
suspension (Figure 3D). To complement these results, we also
generated two stable Bit1 knockdown A549 derived clones, namely
Bit1 shRNA1 and Bit1 shRNA2, with each clone expressing a
distinct Bit1 shRNA that targets a different sequence in the 39
noncoding region of Bit1 mRNA. In parallel, stable control
shRNA clones 1 and 2 were generated from the nontargeting
scrambled shRNAs. As shown in Figure 3E, the stable Bit1
shRNA1 and shRNA2 showed a reduction in Bit1 expression by
Bit1 Exhibits Tumor Suppressive Function in Lung Cancer
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70% and 80% respectively as compared to control shRNA clones.
The stable Bit1 shRNA1 and shRNA2 were then combined to
generate the Bit1 shRNA pool while the control shRNA clones 1
and 2 comprised the control shRNA pool (Figure 3E). Consistent
with the data derived from siRNA studies, the Bit1 shRNA pool
displayed a significantly reduced level of apoptosis than the control
shRNA pool following a 72 h culture in suspension (Figure 3F).
Consistent with the lack of effect of ectopic Bit1 on the
mitochondrial pathway (Figure 2D), the observed enhanced
anoikis resistance in Bit1 knockdown cells was not associated with
changes in the expression levels of the Bcl-2 family of apoptosis
regulators (Figure S4). These findings, in conjunction with our
results indicating that exogenous mitochondrial Bit1 can induce
anoikis, provide strong evidence that the Bit1 apoptotic pathway
represents an important caspase-independent anoikis mechanism
in lung cancer cells.
Bit1 is a Negative Regulator of Anchorage-independent
Growth of Lung Cancer Cells
The anchorage-independent growth potential of malignant cells
is dependent on their ability to resist anoikis [1,2]. Here, we
investigated whether Bit1 can regulate the anchorage-independent
growth capability of A549 cells using an in vitro soft agar assay. As
shown in Figures 4A and 4B, the vector transfected cells exhibited
numerous colonies in soft agar after two week incubation. In stark
contrast, mitochondrial Bit1 treated cells showed a reduction in
the number and sizes of colonies, suggesting impairment of their
anchorage-independent growth. The compromised growth of Bit1
transfected cells on semisolid medium was further quantified by
alamar blue staining (Figure 4C).
We also tested the ability of Bit1 shRNA and control shRNA
pools to grow in an anchorage-independent environment.
Consistent with their enhanced anoikis resistance, the stable Bit1
shRNA pool showed greater ability to grow in soft agar than the
control shRNA pool (Figures 4D and 4E). Following a shorter
period of 10 day incubation, it was evident that the Bit1 shRNA
pool exhibited a greater number of larger colonies as compared to
control shRNA pool. The enhanced anchorage-independent
growth ability of Bit1 shRNA pool was quantified by alamar blue
assay (Figure 4F). It is noteworthy that in monolayer culture the
Bit1 shRNA and control shRNA pools exhibited similar anchor-
age-dependent growth kinetics (Figure S5). Collectively, these
results indicate a role of Bit1 in suppressing the anchorage-
independent growth potential of lung cancer A549 cells.
Figure 1. Anoikis insensitivity of A549 cells is associated with lack of caspase activation. A. Cells were cultured being attached (A) or
detached from the ECM for 24 hours (D24) and 48 hours (D48) and were harvested for apoptosis analysis using the Cell Death Elisa ELISA. In parallel,
cells were also treated with 1 mM staurosporine (STS) for 24 hours and subjected to Cell Death Elisa ELISA. B. Cytosolic fractions were obtained from
cells in A and analysed for the presence of cytochrome c by western blot. C. The presence of caspase-3-like activity in the cell lysates from cells
treated in A was determined by the cleavage of a fluorescent substrate z-DEVD-AFC (DEVD). D. and E. Cells in A were subjected to western blotting to
detect the processing of pro-caspase 3 (D) and PARP (E). In A and C, three independent experiments were performed in triplicates, * indicates p,0.05
as compared to attached conditions (Student’s t test).
doi:10.1371/journal.pone.0101564.g001
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TLE1 Blocks Bit1-induced Anoikis by Sequestering AES in
the Nucleus
In addition to integrin mediated cell attachment, the only other
anti-apoptotic factor that can block Bit1 apoptosis is the groucho
corepressor TLE1 protein [11]. TLE1 has recently been shown to
be a lung specific oncogene [16], but its underlying oncogenic
function has not been established. Here, we examined whether
TLE1 may protect lung cancer cells from anoikis induced by Bit1.
To address this possibility, A549 cells were cotransfected with C-
terminally myc-tagged Bit1 and/or full length GFP-tagged TLE1
construct and then cultured on poly-HEMA coated plates. The
ectopic expression of mitochondrial Bit1 and TLE1 was confirmed
by immunoblotting (Figure 5A). Consistent with our previous
findings ([11–15], Figure 2A), detachment induced a higher level
of apoptosis in Bit1 transfected cells than in control cells
(Figure 5B). Importantly, exogenous TLE1 attenuated the high
level of anoikis in mitochondrial Bit1 transfected cells. Further-
more, ectopic TLE1 also inhibited the apoptosis induced by
targeted expression of Bit1 in the cytoplasm (Bit1 cyto) in A549
cells (Figure 5C). To further substantiate the protective effect of
TLE1 on Bit1 anoikis, we downregulated endogenous TLE1
expression and examined its effect on Bit1 anoikis function.
Knockdown endogenous TLE1 expression in A549 cells was
performed via a specific TLE1 siRNA SMART pool. The TLE1
siRNA duplexes showed a significant 50–60% downregulation of
endogenous TLE1 expression in A549 cells (Figure 5D). The
efficacy and specificity of the TLE1 siRNAs in downregulating
TLE1 protein was also confirmed in cells expressing a GFP-tagged
human TLE1 (Figure S6). Suppression of endogenous TLE1
resulted in increased susceptibility of A549 cells to Bit1-induced
anoikis (Figure 5E). Collectively, these findings indicate a critical
role of TLE1 in suppressing the Bit1 anoikis pathway in A549
cells.
Following its release to the cytoplasm, mitochondrial Bit1 binds
to AES and the resulting Bit1-AES complex is the pro-apoptotic
component that mediates the Bit1 apoptotic effect [11]. Consistent
with this notion, the AES null lung cancer cell line HOP-92
remained resistant to Bit1-mediated apoptosis (Figure 5C). To
address the mechanism underlying the inhibitory effect of TLE1
on Bit1 anoikis function, we examined whether nuclear TLE1 may
inhibit the Bit1-AES complex formation by competitive binding to
and sequestering AES protein (which normally shuttles between
the nuclear and cytoplasmic compartments [21,22]) in the nucleus.
Exogenous TLE1 expression decreased the levels of Bit1-AES
complex (Figure 6A) and resulted in significant enrichment of AES
in the nucleus (Figure 6B). The sequestration of AES in the nucleus
Figure 2. Mitochondrial Bit1 induces anoikis in A549 cells. A. Cells were transfected with the C-terminally myc-tagged mitochondrial localized
Bit1 (Bit1 mito) or the empty vector construct. 24 h post-transfection, cells were cultured being attached or detached from the ECM. Following 48 h
in culture, cells were harvested and analyzed for apoptosis by measuring the amount of DNA histone fragments (Cell Death Elisa). B and C. Cells were
transfected with the N-terminally myc tagged cytoplasmic localized Bit1 (Bit1 cyto) (B), Bit1 cell death domain (CDD) (C), or vector construct and 48 h
later, cells were subjected to Cell Death ELISA. D. Vector or Bit1 mito transfected cells were cultured being attached (A) or detached (D) from the ECM
for the indicated times. Cells were then harvested and subjected to western blotting against specific antibodies to caspase-3, PARP, Bcl-2, Bcl-xl, Bax,
Bad, myc, and B-actin. E. Bit1 mito transfected cells were cultured in attached or detached conditions in the presence of z-Vad-fmk (50 uM) or DMSO
for 48 h. Cells were then harvested and subjected to Cell Death ELISA. In A, B, and C, three independent experiments were performed in triplicates,
* indicates p,0.05 by Student’s t test.
doi:10.1371/journal.pone.0101564.g002
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by TLE1 was in part mediated by the association of TLE1 with
AES (Figure 6C) as previously documented [21,22]. Taken
together, these findings indicate TLE1 is a suppressor of the Bit1
anoikis pathway through nuclear sequestration of AES.
Downregulation of Bit1 Promotes Tumorigenicity in
Nude Mice
To address the role of Bit1 on tumor growth in vivo, we
subcutaneously injected control shRNA and Bit1 shRNA clonal
pools in nude mice. As shown in Figure 7A, we observed a
significant increase in the growth rate of Bit1 shRNA tumors as
compared to control shRNA tumors as assessed by two
independent experiments. Seven weeks post-injection, the tumors
were surgically excised and weighed (Figures 7B and 7C). The
average weight of Bit1 shRNA tumors was approximately 3-fold
heavier than the control shRNA tumors (Figure 7C). These
findings indicate that loss of Bit1 expression confers enhanced
tumorigenicity of A549 cells in a mouse xenograft model.
As malignant cells form a subcutaneous three-dimensional
tumor in vivo, a significant proportion of these cells are deprived of
proper contacts with the basement membrane and subject to
apoptosis. Based on the ability of the Bit1 cell death pathway to
effectively trigger apoptosis and anoikis in lung cancer cells in vitro
(Figures 2A–2C) and the recent report demonstrating that
exogenous Bit1 CDD induces apoptosis in human breast tumor
xenografts in vivo [19], the level of apoptosis in control and Bit1
knockdown tumor xenografts was evaluated by subjecting serial
tumor tissue sections to in situ TUNEL assay (Figures 7D and 7E).
The TUNEL-stained control tumor sections exhibited localized
apoptosis as evidenced by the presence of numerous apoptotic cells
particularly in the middle of the tumors. In contrast, fewer
apoptotic cells were observed in Bit1 knockdown tumors
(Figures 7D and 7E). These findings suggest that the enhancement
of tumorigenicity in Bit1 knockdown cells is in part due to reduced
basal apoptosis and are in agreement with previous published data
showing strong inhibition of breast tumor xenograft growth in vivo
by ectopic Bit1 CDD treatment [19].
Bit1 is Downregulated in Human Lung Tumors
Based on our findings that downregulation of Bit1 expression
enhances the in vivo tumorigenecity of A549 cells, we examined the
possibility that Bit1 expression is suppressed in human lung
Figure 3. Knockdown of Bit1 expression protects A549 cells from anoikis. A. and B. Cells were cultured in attached (A) or detached (D)
conditions for the indicated times and then subjected to subjected to Cell Death ELISA (A) or western blotting (B) with antibodies against caspase-3,
PARP, and B-actin. In A, three independent experiments were performed in triplicates; *, p,0.05 as compared to attached cells (Student’s t test). C.
and D. Cells were transfected with control- or Bit1 specific siRNAs, and 48 h later, cells were subjected to immunoblotting (C) with antibodies against
Bit1 and B-actin to confirm the knockdown of Bit1 expression. In parallel, control- and Bit1- siRNA treated cells were cultured in attached (A) or
detached (D) conditions for the indicated times and subjected to Cell Death Elisa (D). E and F. Stable A549 control shRNA and Bit1 shRNA knockdown
clones and pools were generated (as described in materials and methods) and subjected to western blotting (E) using specific antibodies to Bit1 and
B-actin. In F, the control shRNA and Bit1 shRNA pools were cultured in attached (A) or detached (D) conditions for the indicated times and
subsequently analysed for apoptosis by Cell Death Elisa. In A, D, and F, three independent experiments were performed in triplicates, * indicates p,
0.05 as compared to control cells (Student’s t test).
doi:10.1371/journal.pone.0101564.g003
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cancers. Immunohistochemistry staining of human lung tumor
tissue microarrays was performed using an affinity purified
polyclonal antihuman Bit1 antibody [14,15]. In normal lung, the
columnar epithelial cells lining the bronchial mocusa and the
alveolar epithelial cells showed strong cytoplasmic immunoreac-
tivity for Bit1 (Figure 8Ai,ii, indicated by the bolded arrow). Using
the strong immunoreactivity of the normal bronchial and alveolar
epithelial cells as an internal control, cytoplasmic staining of the
tumor cells from multiple cores was evaluated. Immunoreactivity
was graded as 0 (none), 1 slight, 2 (moderate), or 3 (strong) as
described in materials and methods. Significant suppression of Bit1
(grade 0 and 1) was found in 14 of 20 (70%) of the squamous cell
carcinomas (Figure 8Aiii,iv, viii), 40 of 71 (56%) of the
adenocarcinomas (Figure 8Av,vi), and in 4 of 8 (50%) of the large
cell undifferentiated carcinomas (Figure 8Avii). Interestingly, we
found that in some of the NSCLC lesions residual Bit1 expression
is present or retained in epithelial cells closest to the lumen
(Figure 8A iv and viii, unbolded arrow) as well as in nearby
inflammatory cells (Figure 8Aiii, unbolded arrow) while Bit1
expression is completely lost in more dysplastic cells that have
invaded the underlying connective tissue (Figure 8A iii, iv and viii,
bolded arrow). Figure 8B shows the average Bit1 immunostaining
intensity in various types of NSCLC tissues as compared to normal
bronchial and alveolar epithelial cells. These findings indicate that
Bit1 expression is selectively lost in a fraction of various types of
NSCLCs and suggest that loss of Bit1 may contribute to lung
tumorigenesis.
Discussion
Bit1 is a mitochondrial protein which is part of an apoptosis
pathway that is uniquely regulated by integrin-mediated cell
attachment [11]. Following loss of cell attachment, Bit1 is released
to the cytosol to induce a caspase-independent form of apoptosis,
which can only be suppressed by integrin-mediated cell adhesion.
Considering that cell attachment appears to be the only up-stream
treatment that can effectively block Bit1 apoptosis, Bit1 may play a
special role in anoikis as documented in several cellular model
systems [11–15]. Since anoikis resistance is a critical determinant
of transformation, we hypothesize that suppression of Bit1 function
is an alternative mechanism by which malignant cells resist anoikis
and endow themselves with enhanced anchorage-independent
Figure 4. Bit1 attenuates the anchorage-independent growth of A549 cells. A., B. and C. Cells transfected with vector or Bit1 mito construct
were subjected to soft agar assay as described in materials and methods. The representative colonies are shown in A. The extent of colony formation
was quantified by counting the number of visible colonies with a diameter greater than 30 uM (B) and by alamar blue staining and fluorescent assay
(C). D, E and F. The stable A549 control shRNA and Bit1shRNA knockdown pools were also subjected to soft agar assay. The representative colonies
are visualized in A and quantified by counting the number of visible colonies (E) and alamar blue assay (F). In B, C, E and F, three independent
experiments were performed in triplicates, * indicates p,0.05 as compared to corresponding control cells (Student’s t test).
doi:10.1371/journal.pone.0101564.g004
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Figure 5. TLE1 inhibits Bit1 anoikis function. A. and B. A549 cells were transfected with Bit1 mito and/or with GFP-tagged TLE1 construct. 24 h
post transfection, the expression of exogenous Bit1 and TLE1 in transfected cells was confirmed by western blotting using specific antibodies to myc
and GFP tags. The amount of plasmid transfected into cells was normalized with the vector construct. In parallel, transfected cells were grown in
suspension for 48 h and then subjected to Cell Death ELISA assay (B). C. A549 can HOP-92 cells were transfected with Bit1 cyto or GFP-TLE1 construct.
48 h post-transfection, cells were harvested and analyzed for apoptosis by Cell Death Elisa. D. A549 cells were transfected with control- or TLE1
specific siRNAs, and 48 h later, cells were subjected to immunoblotting with antibodies against TLE1 and B-actin to confirm the knockdown of TLE1
expression. E. A549 cells were transfected with vector or Bit1 mito construct, and 24 hr later, the mitochondrial Bit1 treated cells were transfected
with control- or TLE1-siRNAs as indicated. Cells were then cultured in suspension for 48 hr and subjected to Cell Death Elisa. In B, C, and E, three
independent experiments were performed in triplicates, * indicates p,0.05 by Student’s t test.
doi:10.1371/journal.pone.0101564.g005
Figure 6. TLE1 blocks Bit1-AES complex formation by sequestering AES in the nucleus. A. and B. A549 cells were transfected with GFP-
TLE1 together with N-terminally myc tagged Bit1 construct. The amount of DNA was normalized with the empty vector in each transfection. 24 h
post-transfection, cells were harvested and cell extracts were prepared, immunoprecipitated with agarose-immobilized anti-myc, and immunoblotted
with anti-AES and anti-myc antibodies (A). In parallel, transfected cells were subjected to nuclear isolation as indicated in the materials and methods.
The resulting nuclear fraction was run on SDS-PAGE and western blotted with an anti-AES antibody. The Histone H2B was used as a nuclear marker
(B). C. A549 cells were transfected with vector or GFP-TLE1 construct, and 24 h post-transfection, cells were subjected to immunoprecipitation with
agarose-immobilized anti-GFP and western blotting with anti-AES and anti-GFP antibodies.
doi:10.1371/journal.pone.0101564.g006
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growth potential in vitro and tumorigenecity in vivo. We were
particularly interested in examining the role of Bit1 in lung
tumorigenesis based on existing evidence indicating that the Bit1
apoptotic pathway is nonfunctional in lung cancer. Through the
NIH genomics and ONCOMINE database, we found that the
Bit1 mRNA expression (via electronic northern and SAGE
analysis) is significantly downregulated in human lung cancer
relative to its normal counterpart. The loss of Bit1 expression in
human lung tumors was subsequently confirmed via immunohis-
tochemistry staining of lung tumor tissue arrays (Figure 8). A
recent study indicated that TLE1, the sole known inhibitor of Bit1
apoptotic function, is a putative lung specific oncogene and is
overexpressed in human lung tumors [16]. Downregulation of Bit1
expression and/or overexpression of TLE1 are potential mecha-
nisms that could lead to disruption of the Bit1 pathway. In this
report, we provide the first evidence of the tumor suppressive
function of Bit1. Our findings also indicate that a potential
mechanism underlying the TLE1 oncogenic function is to protect
lung cancer cells from Bit1 induced anoikis.
A critical determinant of tumor aggressiveness and progression
is the acquisition of anoikis resistance by malignant cells. Two
molecular pathways are involved in the induction of anoikis, and
both converge on caspase activation to effect nuclear signs of
apoptosis [5–9]. Considering the pivotal role of caspases in anoikis
induction, defect or inactivation of caspases could be a major
contributory factor in the emergence of anoikis insensitivity of
cancer cells. Indeed, we show here that the anoikis resistance of
A549 NSCLC cells is associated with lack of significant
mitochondrial release of cytochrome c and caspase activity. The
latter was evidenced by the absence of processing and cleavage of
the executioner caspase 3 and the downstream nuclear PARP
protein (Figure 1). These findings are consistent with previous
reports demonstrating that the chemoresistance of NSCLC is in
part due to a deficiency in cytochrome c/caspase-dependent
apoptotic pathway [17,18]. Despite the compromised caspase-
dependent pathway, we show here that exogenous mitochondrial
Bit1 can resensitize NSCLC cells to anoikis. Furthermore,
downregulating endogenous Bit1 expression in NSCLC cells
further enhances their anoikis insensitivity after a prolonged
culture in suspension. Hence, the loss of Bit1 expression in human
lung tumors (Figure 8) may represent an important mechanism by
which NSCLC cells circumvent anoikis.
The molecular mechanism underlying Bit1 anoikis function
remains to be fully elucidated. Following its release to the
cytoplasm as a result of loss of cell attachment, Bit1 forms a
complex with the transcriptional regulator protein Amino-terminal
Enhancer of Split (AES) [11]. The formation and abundance of
the Bit1/AES complex is likely critical to Bit1 apoptotic activity
[11–15]. We have shown previously that the level of the Bit1-AES
complex determines the extent of Bit1-mediated apoptosis and is
Figure 7. Suppression of Bit1 enhances tumorigenecity of A549 cells in vivo. A. A549 derived control shRNA and Bit1 shRNA cells (1.06106)
were injected subcutaneously in 8 week old BALB/c nude mice. Tumors were measured periodically with a calliper on the days after injection as
indicated. B. and C. Mice were anesthetized and sacrificed on the day 35 after injection. Subcutaneous tumors were surgically excised, and the tumors
were then photographed (the representative tumors are shown in (B) and weighed (C). In D and E, tissue sections of control shRNA and Bit1 shRNA
xenografts were subjected to TUNEL assay to detect cellular apoptosis. Representative images of TUNEL stained tumor sections are shown in (C).
Arrows indicate apoptotic cells characterized by a brown staining. D. TUNEL positive tumor cells in serial sections of control shRNA and Bit1 shRNA
tumors were quantified. In C and E, * indicates p,0.05 as compared to control tumors (Student’s t test).
doi:10.1371/journal.pone.0101564.g007
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regulated by the cytoplasmic concentration of Bit1 and AES.
While AES exists in both the cytoplasmic and nuclear compart-
ments [21,22], the presence and/or concentration of Bit1 in the
cytoplasm will likely serve as a rate determining event in the Bit1/
AES complex formation. Cytoplasmic Bit1 presence may result
from incomplete import of Bit1 into mitochondria (such as
through forced expression of Bit1 tagged at the N-terminus (Bit1
cyto)) or its release from mitochondria as a result of compromised
mitochondrial membrane stability (such as in cells undergoing
anoikis). As documented in our previous studies [11–15], the
formation of the pro-apoptotic Bit1-AES complex is negatively
regulated by the nuclear TLE1 corepressor at least in part by
sequestering AES in the nucleus (Figure 6). To further examine
how the Bit1/AES complex induces apoptosis, our current
research work focuses on the potential regulation of the TLE1
transcriptional program by the Bit1/AES complex. Numerous
studies have reported that TLE1 exhibits pro-survival and
antiapoptotic function in several cellular models [23–25]. Hence,
it is conceivable that the nuclear TLE1 corepressor controls an
anti-apoptotic transcriptional program. Shutting off the TLE1
anti-apoptotic transcriptional machinery may represent an
important molecular event underlying Bit1 apoptosis. It is
interesting to speculate that suppression of the TLE1 transcrip-
tional machinery by the Bit1/AES axis may lead to expression
and/or activation of nuclear enzymes that could effect DNA
fragmentation and nuclear signs of apoptosis. Thus, characteriza-
tion of the anti-apoptotic TLE1 transcriptional program via
identification of the downstream target genes may provide
mechanistic insights into the Bit1 apoptotic pathway.
The TLE1 corepressor has recently been shown to be a putative
lung oncogene [16]. Allen et al. 2006 found that transgenic mice
carrying the human TLE1 homologue, Grg1, develop lung
adenocarcinomas. Consistent with its lung oncogenic function,
TLE1 was found to be upregulated in a significant fraction of
human lung carcinomas. The molecular mechanism and cellular
basis of TLE1 oncogenic function, however, remain to be
determined. In this report, we show that TLE1 functions to
protect lung cancer cells from Bit1-induced anoikis. While
downregulation of endogenous TLE1 expression is sufficient to
enhance the sensitivity of NSCLC cells to Bit1 anoikis, exogenous
TLE1 attenuated Bit1 anoikis. The ability of TLE1 to protect
NSCLC cells from Bit1 anoikis may provide impetus for induction
and enhancement of anchorage-independent growth. Considering
that anchorage-independent potential is a determinant of trans-
Figure 8. Bit1 is downregulated in NSCLC tissues. A. Lung tumor tissue array slides were stained with the affinity purified rabbit anti-Bit1
antibody. Images are representative of each respective case type: normal lung (i, ii 106), squamous cell carcinoma (iii, iv, viii 106), adenocarcinoma (v,
vi 106) and large cell carcinoma (vii). B. The average Bit1 immunostaining intensity in normal bronchial and alveolar epithelial tissues and in various
types of NSCLC cancer was determined as described in materials and methods. The normal bronchial and alveolar epithelial tissues was statistically
significant from the NSCLC tumors using the ANOVA and subsequent Tukey post-hoc analysis (*, P,0.05).
doi:10.1371/journal.pone.0101564.g008
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formation and tumorigenesis, the ability of TLE1 to block the Bit1
anoikis pathway may contribute to its oncogenic function in lung
carcinoma.
Avoidance of apoptosis is one of the hallmarks of cancer, and
the molecular pathways of this process are not fully understood. In
particular, the role of alternative caspase-independent cell death
mechanisms in tumorigenesis has not been documented. Here, we
show evidence that the integrin-regulated caspase-independent
apoptosis effector Bit1 exerts a tumor suppressive effect in lung
carcinoma. Downregulation of Bit1 expression in the human
NSCLC A549 cell line is sufficient to enhance colony formation in
soft agar and accelerate tumor growth in immunocompromised
animals. Consistent with its tumor suppressor function, Bit1
expression is downregulated in advanced stages of lung carcinoma.
It is interesting to note that disruption of the Bit1 pathway can also
be achieved via overexpression of its inhibitor TLE1, which has
been shown to be upregulated in human lung cancer [16]. As a
potential tumor suppressor of lung cancer, selective targeting of
Bit1 in lung tumors may serve as a therapeutic strategy to
reactivate the apoptotic mechanism in lung cancer cells and block
tumor progression. In line with this notion, selective tumor
delivery of the cell death domain (CDD) of Bit1 was shown to be
effective in regressing the growth of caspase-resistant breast tumors
in xenograft models [19]. Currently, we are examining the utility
of the CDD peptide in inhibiting the growth of lung carcinomas in
vivo. Given the importance of anoikis resistance in tumor
progression and metastasis, understanding how the Bit1 apoptotic
pathway may impact lung cancer metastasis remains an important
area of investigation. Indeed, we have previously shown Bit1 may
function as an inhibitor of metastasis in melanoma and breast
tumors [14]. The significant loss of Bit1 expression in the highly
aggressive human NSCLC tissues as shown in this report
underscores the potential in vivo role of Bit1 in lung metastatic
disease.
In conclusion, we have found that the Bit1 apoptotic pathway is
a viable cell death pathway that can circumvent the anoikis
resistance of NSCLC. While targeting Bit1 expression in the
mitochondria inhibits anoikis resistance and anchorage-indepen-
dent growth of NSCLC cells, specific downregulation of endog-
enous Bit1 in these cells further potentiated their anoikis
insensitivity and anchorage-independent growth in vitro and
tumorigenic growth in vivo. The findings of this study provide
the first evidence in support of Bit1 as a potential tumor suppressor
in human lung cancer and raise the possibility that the previously
reported oncogenic function of TLE1 is to attenuate the Bit1
anoikis pathway.
Supporting Information
Figure S1 Exogenous mitochondrial Bit1 (Bit1 mito)
expression induces anoikis in H460 cells. Cells were
transfected with the C-terminally myc-tagged mitochondrial
localized Bit1 (Bit1 mito) or the empty vector construct. 24 h
post-transfection, cells were cultured being attached or detached
from the ECM. Following 48 h in culture, cells were harvested and
analyzed for apoptosis by measuring the amount of DNA histone
fragments (Cell Death Elisa). Three independent experiments were
performed in triplicates, * indicates p,0.05 by Student’s t test.
(TIF)
Figure S2 Exogenous expression of cytoplasmic local-
ized Bit1 induces apoptosis in H460 cells. Cells were
transfected with the N-terminally myc tagged cytoplasmic
localized Bit1 (Bit1 cyto) or vector construct and 48 h later, cells
were subjected to Cell Death ELISA. Three independent
experiments were performed in triplicates, * indicates p,0.05 as
compared to control cells (Student’s t test).
(TIF)
Figure S3 Ectopic expression of Bit1 CDD peptide
induces apoptosis in H460 cells. Cells were transfected with
the N-terminally myc tagged Bit1 cell death domain (CDD) or
vector construct and 48 h later, cells were subjected to Cell Death
ELISA. Three independent experiments were performed in
triplicates, * indicates p,0.05 as compared to control cells
(Student’s t test).
(TIF)
Figure S4 Knockdown of Bit1 does not alter the
expression levels of the Bcl-2 family of proteins in
A549 cells. Stable A549 derived control shRNA and Bit1 shRNA
pool of cells were cultured in attached (A) or detached (D)
conditions for the indicated time and subsequently subjected to
western blotting with antibodies against Bcl-2, Bcl-xl, Bax, Bad,
Bit1, and B-actin.
(TIF)
Figure S5 Knockdown of Bit1 does not alter the
anchorage-dependent growth of A549 cells. Stable A549
derived control shRNA and Bit1 shRNA pool of cells were plated
onto regular tissue culture plates and the growth of cells was
quantified by MTT assay at the indicated time points.
(TIF)
Figure S6 Exogenous GFP-TLE1 is downregulated by
the specific TLE1siRNAs. A549 cells were transfected with the
vector or GFP-TLE1 construct, and 24 h later cells were
transfected with control- or TLE1 specific siRNAs as indicated.
36 h post-siRNA transfection, cells were subjected to immuno-
blotting with antibodies against GFP and B-actin to confirm the
knockdown of exogenous TLE1 expression.
(TIF)
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